NASDAQ:AVLN Avalyn Pharma (AVLN) Stock Price, News & Analysis $25.83 -1.31 (-4.83%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Avalyn Pharma Stock (NASDAQ:AVLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avalyn Pharma alerts:Sign Up Key Stats Today's Range$25.28▼$27.2050-Day Range$23.33▼$38.9752-Week Range$22.24▼$40.17Volume961,285 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$60.00Consensus RatingModerate Buy Company Overview Avalyn Pharma, Inc. (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects. Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company has also advanced AP02, an inhaled formulation of nintedanib, as part of its pipeline of localized treatments for fibrotic lung disease. These candidates are intended to address significant unmet needs among patients whose conditions can progressively impair lung function. Avalyn Pharma is based in the United States and is focused primarily on clinical development and regulatory advancement of its pulmonary medicine pipeline. As a development-stage biotechnology company, its programs remain subject to clinical, regulatory and commercial uncertainties.AI Generated. May Contain Errors. Read More Avalyn Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreAVLN MarketRank™: 3.46282911719 of 5 starsAvalyn Pharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 185th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAvalyn Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAvalyn Pharma has a consensus price target of $60.00, representing about 132.3% upside from its current price of $25.83.Amount of Analyst CoverageAvalyn Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Avalyn Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avalyn Pharma are expected to grow in the coming year, from ($3.86) to ($2.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalyn Pharma is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalyn Pharma is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.31% of the float of Avalyn Pharma has been sold short.Short Interest Ratio / Days to CoverAvalyn Pharma has a short interest ratio ("days to cover") of 6.63.Change versus previous monthShort interest in Avalyn Pharma has recently decreased by 6.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalyn Pharma does not currently pay a dividend.Dividend GrowthAvalyn Pharma does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.71 News SentimentAvalyn Pharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avalyn Pharma this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Avalyn Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avalyn Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsAvalyn Pharma has minimal institutional ownership at this time.Read more about Avalyn Pharma's insider trading history. Receive AVLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalyn Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVLN Stock News HeadlinesAvalyn Pharma Inc.'s Lock-Up Period To Expire on October 27th (NASDAQ:AVLN)October 20, 2026 | americanbankingnews.comAvalyn Pharma (NASDAQ:AVLN) Reaches New 12-Month Low - What's Next?October 16, 2026 | americanbankingnews.comHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading Apple, Tesla, or Bitcoin. He targets overlooked small-cap stocks that can move fast: $1.50 to $98.40 in a week, $6 to $34 in hours, or 49 cents to $10 in days. Now he is sharing the exact setup he watches for before these moves happen.October 27 at 1:00 AM | Tim Sykes (Ad)Avalyn Pharma Inc (AVLN)October 3, 2026 | investing.comRaymond James Initiates Avalyn Pharma With Outperform Rating, $60 Price TargetOctober 2, 2026 | marketscreener.comMAvalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too PriceySeptember 23, 2026 | finance.yahoo.comAvalyn Publishes Phase 1 Data Supporting Lung-Targeted AP02 In Lung DiseaseSeptember 22, 2026 | rttnews.comAvalyn Pharma Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety ProfileSeptember 22, 2026 | marketscreener.comMSee More Headlines AVLN Stock Analysis - Frequently Asked Questions How have AVLN shares performed this year? Avalyn Pharma's stock was trading at $29.49 on April 29, 2026. Since then, AVLN stock has decreased by 12.4% and is now trading at $25.83. How were Avalyn Pharma's earnings last quarter? Avalyn Pharma Inc. (NASDAQ:AVLN) announced its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.05. When did Avalyn Pharma IPO? Avalyn Pharma (AVLN) raised $283 million in an initial public offering (IPO) on Thursday, April 30th 2026. The company issued 16,666,667 shares at $16.00-$18.00 per share. When did the company's lock-up period expire? Avalyn Pharma's lock-up period expired on Tuesday, October 27th. Avalyn Pharma had issued 16,666,667 shares in its public offering on April 30th. The total size of the offering was $300,000,006 based on an initial share price of $18.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Avalyn Pharma's major shareholders? Avalyn Pharma's top institutional investors include Manchester Capital Management LLC. Insiders that own company stock include Sr One Capital Management, Llc and Jill Carroll. View institutional ownership trends. How do I buy shares of Avalyn Pharma? Shares of AVLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2026Today10/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AVLN CIK1540171 Webwww.avalynpharma.com Phone(206) 707-0340FaxN/AEmployees55Year Founded2011Price Target and Rating Average Price Target for Avalyn Pharma$60.00 High Price Target$80.00 Low Price Target$51.00 Potential Upside/Downside+132.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:AVLN) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalyn Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalyn Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
